DNA enzyme to inhibit plasminogen activator inhibitor-1
OwnerSilviu Itescuinventor
Life of this patent
Estimating the term…
Abstract
The present invention provides DNAzymes and ribozymes that specifically cleave PAI-1-encoding mRNA. The present invention also provides antisense oligonucleotides that specifically inhibit translation of PAI-1-encoding mRNA. The invention also provides various methods of inhibiting the expression of PAI-1. Finally the invention provides pharmaceutical compositions containing the instant DNAzymes, ribozymes and antisense oligonucleotides as active ingredients.
Claims38
A catalytic nucleic acid that specifically cleaves an mRNA encoding a Plasminogen Activator Inhibitor-1 (PAI-1) comprising, in 5′ to 3′ order:
- (a) consecutive nucleotides defining a first binding domain of at least 4 nucleotides;
- (b) consecutive nucleotides defining a catalytic domain located contiguous with the 3′ end of the first binding domain, and capable of cleaving the PAI-1-encoding mRNA at a predetermined phosphodiester bond;
- and
- (c) consecutive nucleotides defining a second binding domain of at least 4 nucleotides located contiguous with the 3′ end of the catalytic domain,
- wherein the sequence of the nucleotides in each binding domain is complementary to a sequence of ribonucleotides in the PAI-1-encoding mRNA and wherein the catalytic nucleic acid hybridizes to and specifically cleaves the PAI-1-encoding mRNA.
An oligonucleotide comprising consecutive nucleotides that hybridizes with a PAI-1-encoding mRNA under conditions of high stringency and is between 8 and 40 nucleotides in length.
Dependencies are inferred from the claim text.